Optimizing treatment for metastatic castration‐resistant prostate cancer: Food and Drug Administration‐approved therapies, emerging strategies, and biomarker‐driven approaches
Cancer · 2025
DOI: 10.1002/cncr.70037 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cancer, 2025. Verfasst von Faisal Saeed und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology and Laboratory Medicine, Emory University School of Medicine, Atlanta, Georgia, USA. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Castration-Resistant, Biomarkers, Tumor. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 113 Literaturangaben.
Abstract (Originalsprache)
Metastatic castration‐resistant prostate cancer (mCRPC) remains a lethal stage of disease progression despite substantial therapeutic advancements. Driven largely by androgen receptor (AR) signaling, prostate cancer eventually develops resistance to AR‐directed therapies, necessitating alternative strategies. In recent years, several novel agents have received US Food and Drug Administration approval for mCRPC, including next‐generation AR‐signaling inhibitors, poly(adenosine diphosphate‐ribose) polymerase inhibitors, targeted radioligand therapy, and immunotherapy. Although these treatments have extended survival, resistance mechanisms and optimal sequencing remain key challenges. Molecular profiling has uncovered distinct genomic alterations—such as defects in homologous recombination repair genes and mismatch repair alterations—that guide therapeutic decision making. In parallel, novel treatment modalities are being explored, including AR degraders, antibody–drug conjugates, T‐cell engagers, and epigenetic modulators. This review critically evaluates current US Food and Drug Administration‐approved therapies for mCRPC, examines emerging therapeutic strategies under clinical development, and discusses evolving biomarker‐driven approaches that aim to personalize treatment and improve outcomes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pathology and Laboratory Medicine, Emory University School of Medicine, Atlanta, Georgia, USA.
- Winship Cancer Institute, Emory University, Atlanta, Georgia, USA.
- Department of Hematology and Oncology, Emory University School of Medicine, Atlanta, Georgia, USA.
- Department of Radiology and Imaging Sciences, Emory University School of Medicine, Atlanta, Georgia, USA.
- Department of Radiation Oncology, Emory University School of Medicine, Atlanta, Georgia, USA.
- Department of Urology, Emory University School of Medicine, Atlanta, Georgia, USA.
ORCID-Profile: Faisal Saeed, Mehmet Asim Bilen, Bassel Nazha
Zitieren
APA
Saeed, F., Berchuck, J. E., Bilen, M. A., Gandhi, J. S., Nazha, B., Brown, J. T., Schuster, D. M., Jani, A. B., Yu, J., & Harik, L. R. (2025). Optimizing treatment for metastatic castration‐resistant prostate cancer: Food and Drug Administration‐approved therapies, emerging strategies, and biomarker‐driven approaches. Cancer. https://doi.org/10.1002/cncr.70037
Vancouver
Saeed F, Berchuck JE, Bilen MA, Gandhi JS, Nazha B, Brown JT, et al. Optimizing treatment for metastatic castration‐resistant prostate cancer: Food and Drug Administration‐approved therapies, emerging strategies, and biomarker‐driven approaches. Cancer. 2025. doi:10.1002/cncr.70037
BibTeX
@article{Saeed2025,
author = {Saeed, Faisal and Berchuck, Jacob E and Bilen, Mehmet Asim and Gandhi, Jatin S and Nazha, Bassel and Brown, Jacqueline T and Schuster, David M and Jani, Ashesh B and Yu, Jindan and Harik, Lara R},
title = {Optimizing treatment for metastatic castration‐resistant prostate cancer: Food and Drug Administration‐approved therapies, emerging strategies, and biomarker‐driven approaches},
journal = {Cancer},
year = {2025},
doi = {10.1002/cncr.70037}
}
EUVIMED